Creative Biolabs Launches a Series of New Therapeutic Antibodies Products
New York, US – Apr 24, 2019 – Creative Biolabs, a world-leading supplier of therapeutic antibodies, recently introduced a batch of new therapeutic antibody products, highlighted by chimeric antibodies, humanized antibodies, and antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. Moreover, the company also customs therapeutic antibody products to fulfill the diverse market demands.
Basically, therapeutic antibodies are monoclonal antibodies developed to attack specific cells or proteins for the treatment of a host of diseases, such as immune disorders, cancers, and infections. Their development undergoes about four phages, from murine, chimeric, humanized to full human antibodies. To date, a total of 65 monoclonal antibodies (mAbs) have been approved by FDA for clinical uses. Furthermore, more than 350 are under clinical trials. Thanks to their unique advantages, therapeutic antibodies develop very fast and their striking potency has gained wide recognition.
“This time, our company launches a comprehensive list of new therapeutic antibody products, so as to meet various research requirements. As a whole, our therapeutic antibodies boast many notable advantages. For example, they have rather high affinity, high specificity yet low off-target activity. On top of that, they are unlikely to induce immune response in human bodies. We can guarantee that they are completely endotoxin free,” said a scientist from Creative Biolabs.
Initially, the therapeutic antibodies were derived from murine species. Such antibodies have a short half-life in vivo, with limited ability to reach tumor sites. Those shortcomings lead to the production of chimeric antibodies, which fuse murine variable domains and human constant domains. The chimeric antibodies are 70% human, substantially inducing immunogenicity in humans. With the advancement of antibody engineering technology, scientists further decrease the murine part of antibodies by use of complementarity-determining region (CDR) grafting. The resulting antibodies are known as humanized antibodies, with 85-90% human affinity.
“Besides the chimeric and humanized antibody products, the ADCC (antibody-dependent cellular cytotoxicity) antibody is another highlight. ADCC is a mechanism of cell-mediated immune defense, aiming to inhibit infection by stimulating the humoral immune response. It constitutes a key function of antibodies. By introducing new high-quality ADCC enhanced antibody products, we desire to push forward the related research process. All in all, the new products are really in good quality. I promise that you can always find what you want from our product repertoire,” added another scientist also from Creative Biolabs.
Therapeutic antibodies have been developing very fast as a critical therapy for many diseases. When it comes to the prevention and treatment of diseases, it seems hard not to speak of therapeutic antibodies. It can be predicted that the antibody products will come in higher quality and much more quantities. In some sense, the launch of the new antibody products by Creative Biolabs is exactly a confirmation of this trend.
About Creative Biolabs
As a leader in recombinant antibody discovery and manufacturing, Creative Biolabs is committed to providing its global customers with the most comprehensive range of recombinant antibody products and extensive service portfolio at the most competitive price. Its products range from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CDR) products, antibody-drug conjugates (ADC) to engineered antibodies. It also provides a variety of custom antibody discovery and engineering services.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: www.creativebiolabs.net/
